From Mary Ann Roser’s statesman. com/salud:
Scott & White’s Cancer Research Institute in Temple is seeking patients to take part in a clinical trial testing an intravenous drug that targets malignant T-cell lymphoma, a type of blood cancer.
The trial is open to people living in the Austin area who are willing to be hospital- ized in Temple for five days and are willing to return to be monitored with lab work and/or clinic visits up to four times during the first 30 days. Patients with partial or complete remissions will have follow-up visits during the year and annual visits to assess their response, according to the research institute.
About 15 percent of lymphomas are of T-cell origin, which tend to be chronic and do not respond well to chemotherapy, according to Dr. Arthur Frankel, director of the research institute and of Scott & White’s division of hematology/oncology. Consequently, the institute is seeking new agents that can target and kill the malignant T-cells, such as this drug.
Scott & White’s has enrolled 10 people in the study and hopes to enroll up to 30 more. To be eligible, patients must have failed previous treatment options.
The trial is being financed by the Gateway for Cancer Research foundation, a nonprofit medical research philanthropy, according to Frankel.
For information, contact clinical research coordinator Margarite Grable at firstname.lastname@example.org.